



Iowa Department of Human Services

Kim Reynolds
Governor

Adam Gregg
Lt. Governor

Jerry R. Foxhoven
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

April 4, 2018

Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265
Fairmeadows Room

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) DHS Recommendation Letter – February 2018
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) United Healthcare Community Plan
 - b) Amerigroup
6. Public Comment* (See Conflict of Interest Disclosure Form)
7. ProDUR Edits
 - a) Age Edit
 - i. Smoking Cessation Therapy, Oral & Nicotine Replacement Therapy
 - b) Point of Sale Drug Utilization (DUR) Edits
8. Prior Authorization
 - a) Deutetrabenazine (Austedo) & Valbenazine (Ingrezza) – Initial Review - Updated
 - b) Hepatitis C Treatments – Initial Review
 - c) Janus Kinase Inhibitors – Initial Review
 - d) Biologicals for Arthritis – Initial Review
 - e) Apremilast (Otezla) – Initial Review

- f) Methotrexate Injection – Initial Review
- g) Chronic Pain Syndromes – Initial Review
- h) CNS Stimulants and Atomoxetine – Tabled to June 6, 2018 meeting
- i) Anti-Diabetic Non-Insulin Agents - Second Review

9. Miscellaneous

- a) DUR Digest Vol. 30, No. 3 – Initial Review
- b) MedWatch
- c) Articles of Interest

Nonpharmacologic Treatment of Chronic Pain in Disadvantaged Patients

<https://www.jwatch.org/na46200/2018/03/05/nonpharmacologic-treatment-chronic-pain-disadvantaged>

Smoking Cessation Drug Linked to Cardiac Events

https://www.medscape.org/viewarticle/893111?nlid=121393_2712&%20src=wnl_cmemp_180326_mscpedu_pharm&uac=6217CR&impID=1591024&faf=1

Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers

<https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djx240/4768312?searchresult=1>

10. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting June 6, 2018*****

Learning Resource Center 3550 Mills Civic Parkway, West Des Moines, IA 50265